title: [Treatment of hypertension with urapidil (Ebrantil)].
abstract: Ebrantil has been added to the beta-blockers and/or diuretics in the treatment of 32 patients with moderate and severe hypertension under the conditions of 3-month open clinical experiment. A very good antihypertensive effect was obtained in 31.3% of the treated, moderate--in 65.6% and unsatisfactory--in 3.1%. Ebrantil does not change the heart rate and is, in fact, without any adverse effects.
authors.forename: V
authors.initials: V
authors.lastname: Sirakova
authors.forename: N
authors.initials: N
authors.lastname: Penkov
authors.forename: Kh
authors.initials: Kh
authors.lastname: Kaponov
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002214:Capsules; D003692:Delayed-Action Preparations; D004232:Diuretics / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002214:Capsules; D003692:Delayed-Action Preparations; D004232:Diuretics; D010879:Piperazines; C015568:urapidil
vernacular_title: Lechenie na khipertonichnata bolest s urapidil (Ebrantil).